MIC and serum bactericidal activity of clindamycin against methicillin-resistant and -sensitive Staphylococci
Tóm tắt
Six volunteers were given 600 mg clindamycin intravenously to investigate the serum bactericidal activity (SBA) against 50 methicillin susceptible (MSSA) and 50 methicillin resistantStaphylococcus aureus (MRSA) strains. Minimal inhibitory concentrations (MIC) against MSSA, MRSA and 50 methicillin resistant strains ofStaphylococcus epidermidis (MRSE), of which 50% were slime-producing, were determined. SBA of clindamycin against MSSA and MRSA was equally high (mean reciprocal SBA titer against MSSAvs MRSA 1h after application was 13.0vs 13.45), although MICs against MRSA were markedly higher than against MSSA (MIC 90 of MRSAvs MSSA: 0.06vs>32 mg/l). There was no difference in MICs between slime- and non-slime-producing MRSE.
Tài liệu tham khảo
Wolfson, J. S., Swartz, W., Swartz, M. N. Serum bactericidal activity as a monitor of antibiotic therapy. N. Engl. J. Med. 11 (1985) 968–975.
Boeckh, M., Lode, H. Die Bedeutung der Serumbakterizidie für den Erfolg einer bakteriellen Therapie. Fortschr. Antimikr. Antineoplast. Chemother. 9 (1990) 203–211.
Standiford, H. C., Tatem, B. A. Technical aspects and clinical correlation of the serum bactericidal test. Eur. J. Clin. Microbiol. 5 (1986) 79–87.
Bennet, J. V., Brodie, J. L., Benner, E. J., Kirby, W. M. M. Simplified accurate method for antibiotic assay of clinical specimens. Applied Microbiol. 14 (1966) 170–177.
National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document M7-A2, Villanova, Pa., 10 (1990) 1–31.
National Committee for Clinical Laboratory Standards Methodology for the serum bactericidal test: proposed guidelines. NCCLS document M 21-P, Villanova, Pa., 7 (1987) 7–19.
Standiford, H. C., Drusano, G. L., Fitzpatrick, B., Tatem, B., Schimpff, S. C. Bactericidal activity of ceftazidime in serum compared with that of ticarcillin combined with amikacin. Antimicrob. Agents Chemother. 26 (1984) 339–342.
Karch, K., Lode, H., Hampel, B., Rau, M., Borner, K., Koeppe, P., Wagner, J.: Vergleichende Pharmakokinetik und Serumbakterizidie von Flomoxef, Moxalactam und Cefotetan. Deutsche Gesellschaft für Innere Medizin. 94. Tagung Wiesbaden, 10. bis 14. April 1988.
Baxter, R., Chapman, J., Drew, W. L. Comparison of bactericidal activity of five antibiotics againstStaphylococcus aureus. J. Infect. Dis. 161 (1990) 1023–1025.
Hackbarth, C. L., Chambers, H. F., Sande, M. A. Serum bactericidal activity of rifampicin in combination with other antimicrobial agents againstStaphylococcus aureus. Antimicrob. Agents Chemother. 29 (1986) 611–613.
Eliopoulos, G. M., Willey, S., Reiszner, E., Spitzer, P. G., Caputo, G., Moellering, R. C. In vitro andin vivo activity of LY 146032, a new cyclic lipopeptide antibiotic. Antimicrob. Agents Chemother. 30 (1986) 532–535.
Ponce de Leon, S., Guenthner, S. H., Wenzel, R. P. Microbiologic studies of coagulase-negative staphy lococci isolated from patients with nosocomial bacteraemias. J. Hosp. Infect. 7 (1986) 121–129.